Reagents for reducing leukocyte interference in immunoassays

• US 8,476,079 B2
• Filed: 04/30/2010
• Issued: 07/02/2013
• Est. Priority Date: 04/30/2010
• Status: Active Grant

• Current Assignee: Abbott Point Of Care Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Point Of Care Incorporated (Abbott Laboratories Incorporated)
• Inventors: Campbell, John Lewis Emerson, Davis, Graham, Omakor, John Emegbero, Moss, Adam Roger, Guhados, Ganesh
• Primary Examiner(s): Gabel, Gail R
• Application Number:
  US12/771,634
• Publication Number:
  US 20110269159A1
• Time in Patent Office: 1,159 Days
• Field of Search: 435/4, 435/7.1, 435/14, 435/21, 435/26, 435/287.1, 435/288.5, 435/288.7, 435/287.2, 436/518, 436/524, 436/525, 436/528, 436/175, 436/177
• US Class Current: 436/175
• CPC Class Codes: G01N 2333/475 Assays involving growth factors
• CPC Class Codes: G01N 33/5306 Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
• CPC Class Codes: G01N 33/5375 by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
• CPC Class Codes: G01N 33/54393 Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
• CPC Class Codes: Y10T 436/25125 Digestion or removing interfering materials
• CPC Class Codes: Y10T 436/25375 Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Abstract

Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample such as a whole blood sample with one or more leukocidal reagents that reduce or eliminate the metabolic activity of leukocytes, and performing an immunoassay on the amended sample to determine the concentration of analyte in the sample. Preferably, the sample is amended with one or more enzymes and optionally one or more enzyme substrates and cofactors.

Claims

1. A method of performing an electrochemical immunoassay for a target analyte in a whole blood sample comprising:

contacting the whole blood sample with an oxygen depleting leukocidal reagent, wherein said leukocidal reagent substantially inhibits phagocytic activity of leukocytes in the whole blood sample; and

performing the electrochemical immunoassay on the whole blood sample at an immunosensor to detect a target analyte.

2. The method of claim 1, wherein the leukocidal reagent is a metabolic leukocidal reagent.

3. The method of claim 1, wherein the leukocidal reagent is non-ionic.

4. The method of claim 1, wherein the leukocidal reagent is an oxygen and glucose depleting leukocidal reagent.

5. The method of claim 1, wherein the leukocidal reagent is glucose oxidase.

6. The method of claim 1, wherein the leukocidal reagent is glucose oxidase and glucose.

7. The method of claim 1, wherein the leukocidal reagent is glucose oxidase and glucose, and said leukocidal reagent mixes with the blood sample to provide a glucose oxidase activity above about 3 IU per mL and a glucose concentration above about 500 mg/dL.

8. The method of claim 1, wherein the leukocidal reagent is glucose oxidase and an electron acceptor.

9. The method of claim 1, wherein the leukocidal reagent comprises hexokinase and a source of adenosine-5′

-triphosphate (ATP).

10. The method of claim 1, wherein the leukocidal reagent comprises hexokinase, creatine kinase, adenosine diphosphate (ADP), and creatine phosphate.

11. The method of claim 1, wherein the leukocidal reagent comprises glucose dehydrogenase.

12. The method of claim 1, wherein the leukocidal reagent comprises glucose dehydrogenase, nicotinamide adenine dinucleotide (NAD) oxidase, nicotinamide adenine dinucleotide+hydrogen (NADH) oxidase, and an electron acceptor.

13. The method of claim 1, wherein the leukocidal reagent is selected from the group consisting of dithionite, glucose oxidase, and ascorbate oxidase.

14. The method of claim 1, wherein the immunoassay is a sandwich assay performed by contacting the whole blood sample with the immunosensor comprising an immobilized first antibody to the target analyte, and a labeled second antibody to the target analyte.

15. The method of claim 1, wherein the immunoassay is a competitive assay performed by contacting the whole blood sample with the immunosensor comprising an immobilized first antibody to the target analyte, and a labeled target analyte.

16. The method of claim 1, wherein the whole blood sample is contacted with beads opsonized for leukocytes.

17. The method of claim 1, wherein the leukocidal reagent is glucose oxidase and glucose, and the whole blood sample is contacted with beads opsonized for leukocytes.

18. The method of claim 1, wherein the whole blood sample is amended with an anticoagulant.

19. The method of claim 1, wherein the analyte is selected from the group consisting of Troponin I (TnI), Troponin T (TnT), B-Type Natriuretic Peptide (BNP), N-Terminal pro B-Type Natriuretic Peptide (NTproBNP), pro B-Type Natriuretic Peptide (proBNP), Human Chorionic Gonadotropin (HCG), Thyroid Stimulating Hormone (TSH), Neutrophil Gelatinase-Associated Lipocalin (NGAL), theophylline, digoxin, and phenytoin.

20. A kit for performing an electrochemical immunoassay for a target analyte in a whole blood sample comprising:

an immunosensor;

an oxygen depleting leukocidal reagent, wherein said leukocidal reagent is configured to substantially inhibit phagocytic activity of leukocytes in the whole blood sample, and

immunoassay reagents for detecting the target analyte.

21. The kit of claim 20, wherein the leukocidal reagent is a metabolic leukocidal reagent.

22. The kit of claim 20, wherein the leukocidal reagent is non-ionic.

23. The kit of claim 20, wherein the leukocidal reagent is an oxygen and glucose depleting leukocidal reagent.

24. The kit of claim 20, wherein the leukocidal reagent is glucose oxidase.

25. The kit of claim 20, wherein the leukocidal reagent is glucose oxidase and glucose.

26. The kit of claim 20, wherein the leukocidal reagent is glucose oxidase and glucose, and said leukocidal reagent mixes with the whole blood sample to give a glucose oxidase activity above about 3 IU per mL and a glucose concentration above about 500 mg/dL.

27. The kit of claim 20, wherein the leukocidal reagent is glucose oxidase and an electron acceptor.

28. The kit of claim 20, wherein the leukocidal reagent comprises hexokinase and a source of adenosine-5′

-triphosphate (ATP).

29. The kit of claim 20, wherein the leukocidal reagent comprises hexokinase, creatine kinase, adenosine diphosphate (ADP), and creatine phosphate.

30. The kit of claim 20, wherein the leukocidal reagent comprises glucose dehydrogenase.

31. The kit of claim 20, wherein the leukocidal reagent comprises glucose dehydrogenase, nicotinamide adenine dinucleotide (NAD) oxidase, nicotinamide adenine dinucleotide+hydrogen (NADH) oxidase, and an electron acceptor.

32. The kit of claim 20, wherein the leukocidal reagent is selected from the group consisting of dithionite, glucose oxidase, and ascorbate oxidase.

33. The kit of claim 20, wherein the immunoassay is a sandwich assay and wherein the immunoassay reagents comprise a labeled second antibody to the target analyte, and the immunosensor comprises an immobilized first antibody to the target analyte.

34. The kit of claim 20, wherein the immunoassay is a competitive assay and wherein the immunoassay reagents comprise an immunosensor comprises a labeled target analyte, and the immobilized first antibody to the target analyte.

35. The kit of claim 20, further comprising beads opsonized for leukocytes.

36. The kit of claim 20, wherein the leukocidal reagent is glucose oxidase, and the whole blood sample is contacted with beads opsonized for leukocytes.

37. The kit of claim 20, wherein the whole blood sample is amended with an anticoagulant.

38. The kit of claim 20, wherein the analyte is selected from the group consisting of Troponin I (TnI), Troponin T (TnT), B-Type Natriuretic Peptide (BNP), N-Terminal pro B-Type Natriuretic Peptide (NTproBNP), pro B-Type Natriuretic Peptide (proBNP), Human Chorionic Gonadotropin (HCG), Thyroid Stimulating Hormone (TSH), Neutrophil Gelatinase-Associated Lipocalin (NGAL), digoxin, theophylline, and phenytoin.